Studieoverzicht
Study name: Amgen Tarlatamab - Dellphi304
| Histology | SCLC |
|---|---|
| Tumor stage | Stage IV |
| Host / recruiting sites | LUMC |
| Enrollment | Closed |
| Therapy line | Later line (≥2L) |
| Design |
Open label, gerandomiseerde fase 3 studie |
| Intervention | Tarlatamab vs Topotecan |
| Key outcome parameters | Primaire eindpunt: OS |
| Key inclusion criteria | Histologisch of cytologisch bevestigd relapse SCLC na 1 lijn platinum-bevattend regime |
| Key exclusion criteria | Onbehandelde of symptomatische CNS metastasen of leptomeningeale metastasen |
| Contact information | Log in voor de contactinformatie |